| Dr Alyssa Pabelle Dipalac Vivas, DO | |
|
21212 E Ocotillo Rd, Queen Creek, AZ 85142-9667 | |
| (602) 755-0800 | |
| (480) 571-7973 |
| Full Name | Dr Alyssa Pabelle Dipalac Vivas |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 9 Years |
| Location | 21212 E Ocotillo Rd, Queen Creek, Arizona |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1720460819 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | R2590 (Arizona) | Secondary |
| 207Q00000X | Family Medicine | 007363 (Arizona) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Summit Medical Group Arizona Llc | 3173872835 | 198 |
News Archive
Continuing to drive innovation in endourology, Cook Medical will feature a series of product demonstrations and interactive presentations with a special emphasis on kidney stone management solutions, including the LMA Stonebreaker and Holmium Lasers at the 27th Annual World Congress on Endourology and SWL (shock wave lithotripsy) at the Sheraton Grand Hotel in Munich, Germany from 6-10 October.
Genetic testing may soon prove that prevention is better than cure. However, the emerging practice could have certain less desirable ethical and practical implications.
Santen Inc., the U.S. subsidiary of global ophthalmic pharmaceutical company Santen Pharmaceutical Co., Ltd. (Osaka, Japan), today announced that SAKURA (Study Assessing double‐masKed Uveitis tReAtment) Study 1, the first of two Global Phase III studies evaluating intravitreal injections of sirolimus in patients with non-infectious posterior segment uveitis (NI-PSU), met its primary endpoint.
A new study has characterized and compared the N-glycosylation of the wild type (S-614D) and variant (S-614G) of SARS-CoV-2 S glycoproteins using MS techniques.
› Verified 2 days ago
| Entity Name | Neighborhood Outreach Access To Health |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1942518550 PECOS PAC ID: 3577743764 Enrollment ID: O20110204000504 |
News Archive
Continuing to drive innovation in endourology, Cook Medical will feature a series of product demonstrations and interactive presentations with a special emphasis on kidney stone management solutions, including the LMA Stonebreaker and Holmium Lasers at the 27th Annual World Congress on Endourology and SWL (shock wave lithotripsy) at the Sheraton Grand Hotel in Munich, Germany from 6-10 October.
Genetic testing may soon prove that prevention is better than cure. However, the emerging practice could have certain less desirable ethical and practical implications.
Santen Inc., the U.S. subsidiary of global ophthalmic pharmaceutical company Santen Pharmaceutical Co., Ltd. (Osaka, Japan), today announced that SAKURA (Study Assessing double‐masKed Uveitis tReAtment) Study 1, the first of two Global Phase III studies evaluating intravitreal injections of sirolimus in patients with non-infectious posterior segment uveitis (NI-PSU), met its primary endpoint.
A new study has characterized and compared the N-glycosylation of the wild type (S-614D) and variant (S-614G) of SARS-CoV-2 S glycoproteins using MS techniques.
› Verified 2 days ago
| Entity Name | Summit Medical Group Arizona Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1053810622 PECOS PAC ID: 3173872835 Enrollment ID: O20180814003015 |
News Archive
Continuing to drive innovation in endourology, Cook Medical will feature a series of product demonstrations and interactive presentations with a special emphasis on kidney stone management solutions, including the LMA Stonebreaker and Holmium Lasers at the 27th Annual World Congress on Endourology and SWL (shock wave lithotripsy) at the Sheraton Grand Hotel in Munich, Germany from 6-10 October.
Genetic testing may soon prove that prevention is better than cure. However, the emerging practice could have certain less desirable ethical and practical implications.
Santen Inc., the U.S. subsidiary of global ophthalmic pharmaceutical company Santen Pharmaceutical Co., Ltd. (Osaka, Japan), today announced that SAKURA (Study Assessing double‐masKed Uveitis tReAtment) Study 1, the first of two Global Phase III studies evaluating intravitreal injections of sirolimus in patients with non-infectious posterior segment uveitis (NI-PSU), met its primary endpoint.
A new study has characterized and compared the N-glycosylation of the wild type (S-614D) and variant (S-614G) of SARS-CoV-2 S glycoproteins using MS techniques.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Alyssa Pabelle Dipalac Vivas, DO 21212 E Ocotillo Rd, Queen Creek, AZ 85142-9667 Ph: (602) 755-0800 | Dr Alyssa Pabelle Dipalac Vivas, DO 21212 E Ocotillo Rd, Queen Creek, AZ 85142-9667 Ph: (602) 755-0800 |
News Archive
Continuing to drive innovation in endourology, Cook Medical will feature a series of product demonstrations and interactive presentations with a special emphasis on kidney stone management solutions, including the LMA Stonebreaker and Holmium Lasers at the 27th Annual World Congress on Endourology and SWL (shock wave lithotripsy) at the Sheraton Grand Hotel in Munich, Germany from 6-10 October.
Genetic testing may soon prove that prevention is better than cure. However, the emerging practice could have certain less desirable ethical and practical implications.
Santen Inc., the U.S. subsidiary of global ophthalmic pharmaceutical company Santen Pharmaceutical Co., Ltd. (Osaka, Japan), today announced that SAKURA (Study Assessing double‐masKed Uveitis tReAtment) Study 1, the first of two Global Phase III studies evaluating intravitreal injections of sirolimus in patients with non-infectious posterior segment uveitis (NI-PSU), met its primary endpoint.
A new study has characterized and compared the N-glycosylation of the wild type (S-614D) and variant (S-614G) of SARS-CoV-2 S glycoproteins using MS techniques.
› Verified 2 days ago
Dr. Kaleigh Suhs, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 37100n. Gantzel Rd., Ste. 107, Queen Creek, AZ 85140 Phone: 480-394-4480 Fax: 602-805-2828 | |
Judd A Shafer, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 7205 S Power Rd Ste 100, Queen Creek, AZ 85142 Phone: 480-728-6000 Fax: 480-728-6900 | |
Stephanie Deborah Kotsur, NP Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 21321 E Ocotillo Rd Ste 133, Queen Creek, AZ 85142 Phone: 480-987-5525 Fax: 480-987-5115 | |
Daniel B Hoag, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 20715 E Ocotillo Rd, Suite 102, Queen Creek, AZ 85142 Phone: 480-987-0987 | |
Dr. Dorian Lorrae Richardson, ND Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 36460 N Encanterra Dr, Queen Creek, AZ 85140 Phone: 520-505-1944 | |
Tracey Lynn Cooper, FNP-BC Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 19724 E Emperor Blvd, Queen Creek, AZ 85142 Phone: 520-349-8482 | |
Adelaide Amini, FNP-C Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 21772 S Ellsworth Loop Rd, Queen Creek, AZ 85142 Phone: 480-512-3700 |